EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $712,682 | +15.6% | 32,617 | +0.7% | 0.00% | +100.0% |
| Q2 2023 | $616,639 | -15.8% | 32,384 | -14.2% | 0.00% | -50.0% |
| Q1 2023 | $732,534 | +156.2% | 37,740 | +111.7% | 0.00% | +100.0% |
| Q4 2022 | $285,881 | +4.7% | 17,823 | +2.3% | 0.00% | 0.0% |
| Q3 2022 | $273,000 | -34.1% | 17,423 | -12.5% | 0.00% | 0.0% |
| Q2 2022 | $414,000 | -49.4% | 19,912 | -44.8% | 0.00% | 0.0% |
| Q1 2022 | $818,000 | +144.2% | 36,070 | +97.2% | 0.00% | 0.0% |
| Q4 2021 | $335,000 | -12.8% | 18,293 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $384,000 | +39.1% | 18,165 | +19.9% | 0.00% | 0.0% |
| Q2 2021 | $276,000 | -11.0% | 15,147 | +10.4% | 0.00% | 0.0% |
| Q1 2021 | $310,000 | -6.3% | 13,725 | -17.0% | 0.00% | 0.0% |
| Q4 2020 | $331,000 | -14.7% | 16,528 | +4.0% | 0.00% | -50.0% |
| Q3 2020 | $388,000 | +67.2% | 15,899 | +63.3% | 0.00% | +100.0% |
| Q2 2020 | $232,000 | – | 9,737 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |